Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))

Harold, J.; Bellone, S.; Manavell,; Mutlu, L.; McNamara, B.; Hartwich, T.; Zipponi, M.; Yang-Hartwich, Y.; Demirkiran, C.; Verzosa, M. S. Z.; Choi, J.; Dong, W.; Buza, N.; Hui, P.; Altwerger, G.; Huang, G. S.; Andikyan,; Clark, M.; Ratner, E.; Azodi, M.; Schwartz, P. E.; Santin, A. D.

Links

ORCID

Tools

Export citation

Search in Google Scholar

Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma” (Gynecologic Oncology (2023) 168 (157–165), (S009082582201928X), (10.1016/j.ygyno.2022.11.014))

Journal article published in 2023 by J. Harold, S. Bellone, Manavell, L. Mutlu, B. McNamara, T. Hartwich, M. Zipponi, Y. Yang-Hartwich, C. Demirkiran, M. S. Z. Verzosa, J. Choi, W. Dong, N. Buza, P. Hui, G. Altwerger and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload